Keywords: Sanofi-Aventis, Second-quarter 2010 fiancial results, Genzyme M&A rumors, Lovenox, Law suti, FDA
Sanofi-Aventis 2nd-qtr 2010 earnings up 8%, but firm still mute on Genzyme acquisition; sues over Lovenox
Article | 29 July 2010
Sanofi Aventis posted a strong set of second-quarter 2010 results this morning, but the company’s chief executive Chris Viehbacher, unveiling the financials in Paris, remained tight-lipped about the French drug major’s interest in acquiring troubled US biotechnology firm Genzyme, as has been rumoured for around a week (The Pharma Letter July 26 and 27).
M Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer returns worldwide rights to Celldex Thera’s rindopepimut brain tumor vaccine candidate
- India’s Natco challenges Celgene’s Revlimid patent in USA; new CFO named
- Roche plans job cuts, announcing Operational Excellence initiative
- US FDA makes label change on Pfizer’s Tygacil to reflect increased mortality risk
- Weighted average drug price cuts of 20% for over 4,000 drugs enforced in Greece as of today
